Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rivastigmine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Transdermal
01
Overview
Rivastigmine is a small molecule cholinesterase inhibitor used primarily for the symptomatic treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia. It works by reversibly inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), enzymes responsible for the breakdown of acetylcholine in the brain. By increasing acetylcholine levels, it enhances cholinergic neurotransmission and can improve cognitive function and daily living activities in affected patients. Rivastigmine is available as oral capsules, oral solution, and transdermal patches. It was originally developed by Novartis[4][6][10].
- Brand names
- Exelon艾斯能
- Other names
- 卡巴拉汀利斯的明rivastigmine tartrate重酒石酸卡巴拉汀
02
Targets
AcetylcholinesteraseButyrylcholinesterase
Beyond the preview
Go deeper on rivastigmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rivastigmine.